Roche’s vision loss therapy faricimab extends time between treatments by up to four months
Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
In the YOSEMITE and RHINE studies in DME and the TENAYA and LUCERNE studies in nAMD, approximately half of participants eligible for extended dosing with faricimab were able to be treated every four months in the first year.
Results from the four Phase III studies showed that faricimab, when given at intervals of up to four months, offered non-inferior vision gains compared to Regeneron’s Eylea (aflibercept), given every two months.
Read more: http://www.pharmatimes.com/news/roches_vision_loss_therapy_faricimab_extends_time_between_treatments_by_up_to_four_months_1363226
In the YOSEMITE and RHINE studies in DME and the TENAYA and LUCERNE studies in nAMD, approximately half of participants eligible for extended dosing with faricimab were able to be treated every four months in the first year.
Results from the four Phase III studies showed that faricimab, when given at intervals of up to four months, offered non-inferior vision gains compared to Regeneron’s Eylea (aflibercept), given every two months.
Read more: http://www.pharmatimes.com/news/roches_vision_loss_therapy_faricimab_extends_time_between_treatments_by_up_to_four_months_1363226
